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Abstract 
Review on EPAS1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: ECYT4, HIF2A, HLF, MOP2, 
PASD2, bHLHe73 
HGNC (Hugo): EPAS1 
Location: 2p21 
Local order: RPL26P15 - RPL36AP14 - 
uncharacterized LOC101926974 - EPAS1 - 
uncharacterized LOC101805491 - TMEM247 - 
ATP6V1E2. 
DNA/RNA 
Description 
Genomic size: Starts at 46524541 and ends at 
46613842. 
Transcription 
Transcript length: The gene is comprised of 16 
exons, constituting one main transcript of 5184 base 
pairs. 
Pseudogene 
None described. 
Protein 
Description 
The HIF-2α protein is 870 amino acids long and 
consists of a basic-helix-loop-helix domain, two 
PER-ARNT-SIM domains (A and B), an oxygen-
dependent degradation domain (ODDD) and two 
transcriptional-activation domains (N-TAD and C-
TAD). Two proline residues (P405 in ODDD and 
P531 in N-TAD) and an asparaginyl residue (N847 in 
C-TAD) are subjected to hydroxylation during 
physiologic oxygen tensions, regulating the stability 
and activity of the HIF-2α protein.  
 
Representation of the EPAS1/HIF2A protein with its specific domains specified. Critical hydroxylation sites are indicated. 
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Phosphorylation of HIF-2α at T844 has been 
reported as necessary for its transcriptional 
activation function (Gradin et al., 2002). 
Expression 
In adult human tissue, HIF-2α protein is mainly 
expressed in cells experiencing low oxygen levels, 
and the HIF-2α mRNA has been shown to be 
predominantly expressed in highly vascularized 
tissues (Tian et al., 1997). During human 
embryonic and fetal development, HIF-2α is 
transiently but specifically expressed in cells of the 
developing sympathetic nervous system (SNS) 
(Nilsson et al., 2005; Mohlin et al., 2013). In 
embryonic and adult mouse tissue, the expression 
of HIF-2α mRNA is more or less restricted to 
endothelial cells (Tian et al., 1997; Jain et al., 
1998). In a zebrafish model, the HIF-2α transcript is 
expressed early in brain tissue and blood vessels, 
and later on HIF-2α replaces HIF-1α transcription 
in the notochord (Rojas et al., 2007). 
Localisation 
HIF-2α is part of a transcriptional complex and is 
hence localized mainly in the nucleus upon hypoxic 
induction. However, HIF-2α protein can also be 
detected in the cytoplasm, at hypoxic conditions 
and foremost at more physiological oxygen 
conditions, as demonstrated in cultured cells in 
vitro and in tumor specimens in vivo (Holmquist-
Mengelbier et al., 2006). These findings were 
recently strengthened by the demonstration of a role 
for HIF-2α as part of an oxygen-regulated 
translation initiation complex and presence of HIF-
2α in the cellular polysome fraction (Uniacke et al., 
2012). 
Function 
At lower oxygen tensions, the hydroxylation of 
HIF-2α by prolyl hydroxylases (PHDs) and Factor 
Inhibiting HIF (FIH) is prevented, and the HIF-2α 
subunit relocates to the nucleus where it forms a 
transcriptional complex together with its binding 
partner ARNT (also known as HIF-1β) and co-
factors such as p300 and CBP. By binding to 
hypoxia response elements (HREs) in the promoter 
of target genes, the HIF complex initiates 
transcription of numerous genes involved in a 
variety of tumorigenic cellular processes, including 
angiogenesis, invasion and metastasis, growth, 
dedifferentiation, and apoptosis (Semenza, 2003). 
As mentioned under the Localization section, HIF-
2α has also been demonstrated to be part of a 
hypoxia-regulated translation initiation complex. 
Hypoxia induces HIF-2α to form a complex 
together with RNA-binding protein RBM4 and cap-
binding eIF4E2, and this complex is then recruited 
to a wide variety of mRNAs, promoting active 
translation at polysomes (Uniacke et al., 2012). In a 
recent report, HIF-2α was further shown to protect 
human hematopoietic stem/progenitor cells from 
endoplasmic reticulum (ER) stress-induced 
apoptosis and to enhance the long-term 
repopulating ability of these cells (Rouault-Pierre et 
al., 2013). 
Homology 
HIF-2α is part of the basic helix-loop-helix-PAS 
family of proteins and is structurally related to the 
HIF-1α and HIF-3α subunits. While HIF-3α is 
believed to negatively regulate the other two alpha 
subunits (Makino et al., 2001; Maynard et al., 
2007), HIF-1α and HIF-2α share both sequence 
similarity and target genes. However, despite 48% 
primary amino acid sequence homology between 
HIF-1α and HIF-2α (Tian et al., 1997), it is 
becoming increasingly evident that these two 
proteins also function at distinct sites and during 
differential cellular conditions. 
Mutations 
Germinal 
Functional mutations in human EPAS1 are 
associated with variations in hemoglobin and red 
blood cell concentration (Percy et al., 2008b; Beall 
et al., 2010; Yi et al., 2010). Percy et al. described a 
gain of function mutation in a family with high 
hemoglobin concentrations and erythrocytosis 
(Percy et al., 2008b). Similar mutations, all 
associated with small amino acid substitutions 
leading to protein stabilization, have been reported 
in other clinical cases (Gale et al., 2008; Martini et 
al., 2008; Percy et al., 2008a; van Wijk et al., 
2010). In contrast, EPAS1 mutations associated 
with a loss of function and low hemoglobin 
concentrations have been described in healthy 
individuals living at high altitudes. Extensive 
analysis of genome-wide sequence variations and 
exome sequencing in Tibetans have shown that 
EPAS1 is a key gene mutated in Tibetan 
populations (Beall et al., 2010; Simonson et al., 
2010; Yi et al., 2010; Peng et al., 2011). The 
functional consequence of EPAS1 SNPs associated 
with low hemoglobin concentrations is described as 
adaptation to low oxygen without elevated red 
blood cell production, thereby avoiding high blood 
viscosity creating cardiovascular risks. 
Somatic 
Several studies have recently identified the first 
mutations in any of the HIF alpha subunits in 
cancer. Somatic gain-of-function mutations in exon 
12 of the EPAS1 gene in two patients with 
paraganglioma and associated erythrocytosis results 
in an amino acid substitution in proximity to the 
PHD hydroxylation site and increased protein half-
life and HIF-2α activity (Zhuang et al., 2012). 
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Additional mutations in EPAS1 have also been 
identified in patients with paraganglioma and 
pheochromocytoma without associated 
erythrocytosis (Comino-Mendez et al., 2013), and 
in patients with somatostatinoma and 
paraganglioma (Yang et al., 2013). 
Implicated in 
Renal clear cell carcinoma 
Note 
The predominant loss of von Hippel Lindau in clear 
cell renal cell carcinoma (ccRCC), results in 
defective targeting of HIF-α proteins for 
degradation at normoxia (Gnarra et al., 1994). 
Therefore, both HIF-1α and HIF-2α accumulate 
irrespective of oxygen levels in VHL-defective 
cells and are abundantly expressed in cells of 
ccRCC origin (Krieg et al., 2000).  
For unknown reasons, the expression of HIF-2α is 
more prominent than that of HIF-1α in RCC cell 
lines and tumors and HIF-1α expression is often 
lost in RCC cell lines (Maxwell et al., 1999; Krieg 
et al., 2000).  
Regulation of HIF target genes in RCC cell lines 
are more dependent on HIF-2α than on HIF-1α and 
silencing of HIF-2α in VHL-deficient cells suppress 
tumor growth, suggesting an important role for 
HIF-2α in renal carcinoma (Kondo et al., 2003; 
Carroll et al., 2006). 
Paraganglioma/pheochromocytoma 
Note 
Paraganglioma and pheochromocytoma derive from 
the chromaffin cell lineage of the sympathetic 
nervous system, and notably, genes involved in the 
hypoxic response (e.g. VHL and SDH genes) are 
frequently mutated in these tumors (Neumann et al., 
2002). Recently, somatic mutations in the EPAS1 
gene itself were discovered in two paraganglioma 
patients, describing the first cases of EPAS1 
mutations in any cancer type (Zhuang et al., 2012). 
These gain-of-function mutations lead to increased 
protein half-life and HIF-2α activity, in turn 
resulting in up-regulation of HIF-2α downstream 
target genes, presumably explaining the clinical 
presentation in these patients. In a follow-up study, 
two additional EPAS1 mutations were discovered 
in patients presenting with polycythemia and 
somatostatinoma or paraganglioma (Yang et al., 
2013). These novel mutations lead to disruption of 
the ODD domain-PHD2 interaction and thereby 
result in less ubiquitination and higher activity of 
the HIF-2α protein. In another study, 7 out of 41 
examined patients with pheochromocytoma or 
paraganglioma presented with somatic EPAS1 
mutations, and interestingly, three of these cases 
were also accompanied by an exclusive gain of 
chromosome 2p (Comino-Mendez et al., 2013). 
Neuroblastoma 
Note 
In the childhood tumor neuroblastoma, HIF-2α 
positive tumor cells have been identified in a 
perivascular niche, suggesting a non-hypoxic driven 
expression (Pietras et al., 2008). The HIF-2α 
positive cells display an immature tumor stem cell-
like phenotype and their presence in neuroblastoma 
specimens correlate to poor overall survival 
(Holmquist-Mengelbier et al., 2006; Noguera et al., 
2009). In neuroblastoma cell lines, HIF-2α is 
expressed at hypoxic conditions (1% oxygen) and 
at near end-capillary physiological oxygen levels 
(5% oxygen) (Jogi et al., 2002; Holmquist-
Mengelbier et al., 2006). At prolonged hypoxic 
conditions, HIF-2α is continuously expressed in 
contrast to its homologue HIF-1α. In addition, 
overexpression of HIF-2α in a mouse 
neuroblastoma cell line promoted in vivo tumor 
angiogenesis, while mutant HIF-2α cells formed 
tumors that were highly necrotic (Favier et al., 
2007). 
Glioma 
Note 
Knockdown of HIF-2α expression can reduce 
vascularization but accelerate tumor growth of 
human glioblastoma cells pointing to a role for 
HIF-2α as a tumor suppressor in glioblastoma 
(Acker et al., 2005). In contrast, recent work has 
focused on HIF-2α as a putative glioblastoma 
cancer stem cell (CSC) marker. Specifically, HIF-
2α protein expression co-localizes with CD133 in a 
fraction of tumor cells (McCord et al., 2009) and 
with cancer stem cell markers in glioma specimens 
(Li et al., 2009). Glioblastoma putative CSCs 
respond to hypoxia by induction of HIF2-α (Li et 
al., 2009; Seidel et al., 2010), and inhibiting HIF2-α 
in glioblastoma CSCs decreases self-renewal, 
proliferation and survival in vitro and tumor-
initiating capacity in vivo (Li et al., 2009). In 
addition, elevated HIF2A mRNA levels are 
associated with poor prognosis in glioma patients 
(Li et al., 2009). 
Breast cancer 
Note 
HIF-2α is expressed and associates with high 
vascular density, high c-erbB-2 expression and 
extensive nodal metastasis in breast cancer 
(Giatromanolaki et al., 2006). In a slightly larger 
study, HIF-2α was associated with ABCG2 
expression, histology grade and Ki67 expression in 
invasive ductal carcinoma (Xiang et al., 2012). 
Importantly, in two separate breast cancer cohorts, 
HIF-2α correlate to reduced recurrence-free 
survival, breast-cancer specific survival and 
presence of distal metastasis (Helczynska et al., 
2008). 
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Acute myeloid leukemia 
Note 
Knockdown of HIF-2α in CD34+ acute myeloid 
leukemia (AML) cells reduce engraftment ability in 
irradiated mice (Rouault-Pierre et al., 2013). The 
HIF-2α deficient cells are more susceptible to 
apoptosis as a result of increased ROS and ER-
induced stress indicating that HIF-2α is important 
for AML cell survival. 
Other tumor types 
Note 
Expression of the HIF-2α protein has also been 
reported in other solid tumor types including 
colorectal cancer (Yoshimura et al., 2004), prostate 
cancer (Boddy et al., 2005), non-small cell lung 
cancer (Giatromanolaki et al., 2001), squamous cell 
head-and-neck cancer (Koukourakis et al., 2002), 
nodular malignant melanoma (Giatromanolaki et 
al., 2003) and endometrial adenocarcinoma 
(Sivridis et al., 2002). 
Inflammation 
Note 
Sites of inflammation are often hypoxic due to 
vascular damage and large infiltration of cells. In 
order to operate under this condition, cells of the 
innate immunity adapt by expressing the HIF 
proteins (Fang et al., 2009; Imtiyaz and Simon, 
2010). HIF-2α has been directly coupled to the 
regulation of proinflammatory cytokine expression 
in activated macrophages (Fang et al., 2009; 
Imtiyaz et al., 2010).  
Furthermore, HIF-2α has been detected in bone 
marrow-derived macropahges (BMDMs) and tumor 
associated macrophages (TAMs) of various human 
cancers (Talks et al., 2000). Importantly, HIF-2α is 
essential for TAM migration into tumor lesions 
(Imtiyaz et al., 2010), which in turn will promote 
progression and metastasis of tumor cells (Pollard, 
2004). 
Disease 
Erythrocytosis, see section on germinal mutations. 
Development 
Note 
The four available HIF2A knockout mice display 
substantial differences in phenotype, presumably 
due to strain background. The first knockout mouse 
was created on a 129/SvJ background, and resulted 
in embryonic lethality due to circulatory failure 
during midgestation (Tian et al., 1997). Two of the 
following knockout studies demonstrated a role for 
HIF-2α in vascular development. HIF2A deficient 
embryos from an ICR/129Sv background die in 
utero and display severe post-vasculogenic defects 
(Peng et al., 2000), while HIF2A deficient mice on 
129/Sv x Swiss background display lowered VEGF 
levels (Compernolle et al., 2002). The latter mice 
are embryonically lethal due to respiratory distress 
syndrome and cardiac failure (Compernolle et al., 
2002). HIF-2α is also important in normal 
hematopoiesis, as demonstrated by creating adult 
HIF2A knockout mice by crossing of heterozygous 
129S6/SvEvTac EPAS1 and heterozygous 
C57BL/6J EPAS1 knockout mice (Scortegagna et 
al., 2003b). These adult HIF2A deficient mice 
suffer from cardiac hypertrophy, hepatomegaly, 
oxidative stress and pancytopenia (Scortegagna et 
al., 2003a). In summary, HIF2A knockout studies 
demonstrate important roles for HIF-2α in 
catecholamine synthesis, reactive oxygen species 
(ROS) homeostasis and vascular remodeling during 
development. 
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